BioCentury
BioCentury
ARTICLE | Emerging Company Profile

TenSixteen: Targeting dynamic genome to find driver mutations, catch cancer earlier 

Foresite, GV lead $40M A round to build data platform, Dx assay

By Stephen Hansen, Associate Editor
January 28, 2022 6:48 PM UTC


Access this Article
Request a Trial
Purchase This Article
Log in

BCIQ Company Profiles

Foresite Capital

GV

TenSixteen Bio Inc.

BCIQ Target Profiles

Tet methylcytosine dioxygenase 2 (TET2)

Additional sex combs like 1 (ASXL1)

DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A)

BCIQ Company Profiles

Foresite Capital

GV

TenSixteen Bio Inc.

BCIQ Target Profiles

Tet methylcytosine dioxygenase 2 (TET2)

Additional sex combs like 1 (ASXL1)

DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Cookie Policy
California Privacy Rights
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
LinkedIn
Twitter
RSS
BioCentury
© 2022 BioCentury Inc. All Rights Reserved.
Copyright © 2022 BioCentury Inc. All Rights Reserved.
LinkedIn
Twitter
RSS